Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
Type:
Grant
Filed:
April 21, 2004
Date of Patent:
November 18, 2008
Assignees:
Biogen Idec MA Inc., Emory University
Inventors:
Jeffrey L. Browning, Maryann Puglielli, Rafi Ahmed
Abstract: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a ?-L- or ?-D-2?,3?-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
Type:
Application
Filed:
January 8, 2008
Publication date:
November 13, 2008
Applicants:
Pharmasset, Inc., Emory University, Leland Stanford Junior University
Inventors:
Raymond F. Schinazi, Junxing Shi, Robert Striker
Abstract: Described are methods for inactivating adenine nucleotide transporter proteins in specific tissues of a transgenic nonhuman animal using a conditional knockin/knockout technology such as the Cre-LoxP, Flip-FLP recombinase, or Tet-on/off technologies. Specifically, the Ant2 gene is functionally inactivated in a mouse in liver, with or without the concurrent inactivation of the Ant1 gene. The result is an animal in which the Ant2 gene and accompanying ANT 2 protein is absent in one or more tissues, either in the presence or absence of the Ant1 gene and accompanying protein. The resulting animals, cells, mitochondria, and subcelluar fractions such as the mitochondrial permeability transition pore can then be used to identify agents that affect animal and/or subcellular function via a direct or indirect interaction with the ANT2 protein and/or its Ant2 gene.
Type:
Application
Filed:
October 12, 2007
Publication date:
October 30, 2008
Applicant:
Emory University
Inventors:
Douglas C. Wallace, Grant MacGregor, Katrina Waymire, Shawn E. Levy, James E. Sligh, Jason E. Kokoszka
Abstract: Method for the sterospecific preparation of 2? or 3? deoxy and 2?,3?-dideoxy-?-L-pentafuranonucleoside compounds. 2? or 3? deoxy and 2?,3?-dideoxy-?-L-pentofuranonucleoside compounds are also described. Finally, the invention concerns the use of these compounds, and particularly 2?,3?dideoxy-?-L-fluorocytidine, as drugs, and especially as anti-viral agents.
Type:
Grant
Filed:
September 26, 2003
Date of Patent:
October 21, 2008
Assignees:
The UAB Research Foundation, Emory University, Centre National de la Recherche Scientifique (CNSR)
Inventors:
Gilles Gosselin, Jean-Louis Imbach, Anne-Marie Aubertin, Jean-Pierre Sommmadossi, Raymond F. Schinazi
Abstract: Methods and compositions for modulating mammalian gamete adhesion are provided. Representative modulators of gamete adhesion include, but are not limited to polypeptides comprising at least one discoidin/C domain, and optionally at least one EGF domain. A representative polypeptide includes, but is not limited to SED1 polypeptides (SEQ ID NOs. 2-7), prodrugs, fragments, or derivatives thereof. Methods for identifying modulators of SED1-mediated gamete adhesion are also provided.
Abstract: Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.
Type:
Grant
Filed:
November 15, 2002
Date of Patent:
October 7, 2008
Assignees:
The Rockfeller University, Duke University, Emory University
Inventors:
Stephen T. Warren, Victoria Brown-Kennerly, Peng Jin, Stephanie Ceman, Robert B. Darnell, Jennifer C. Darnell, Jack D. Keene, Scott A. Tenenbaum
Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.
Type:
Grant
Filed:
March 8, 2005
Date of Patent:
October 7, 2008
Assignees:
James and Emory University
Inventors:
J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
Abstract: Compositions and methods for treating neural pathologies are provided. In particular, compositions and methods for treating neural pathologies including axonal degeneration are provided. The compositions include peptide ?-ketomides optionally in combination with a second therapeutic agent. Another aspect of the invention provides compositions and methods for treating hyperproliferative disorders. Exemplary compositions for treating hyperproliferative disorders include an anti-proliferative agent such as paclitaxel, in combination with a calpain inhibitor such as AK295.
Type:
Grant
Filed:
September 25, 2003
Date of Patent:
September 30, 2008
Assignees:
Georgia Tech Research Corporation, Emory University
Abstract: An immunological or immunohematological assay system is disclosed that includes a vessel capable of containing an assay sample, an incubator, a sample separation system, an image acquisition system, and a pipettor. The immunological assay system may also include a washer. Also disclosed is an immunological assay method that includes the steps of placing a immunological assay sample in a vessel, which may include a filter; adding testing reagents to the vessel; incubating the sample and reagent mixture in the vessel; separating the sample and reagent mixture in the vessel into components that have and have not reacted; and analyzing the vessel to determine the presence of interactions between the sample and reagents. The bottom of the vessel is preferably of a material that aids in spreading out the reacted components of the sample evenly over the bottom of the vessel so that interactions can more easily be analyzed.
Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2?,3?-dideoxy-2?,3?-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3?-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5? or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
Abstract: A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5? or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.
Type:
Grant
Filed:
March 28, 2006
Date of Patent:
July 22, 2008
Assignee:
Emory University
Inventors:
Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
Abstract: NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors.
Type:
Grant
Filed:
March 8, 2002
Date of Patent:
May 20, 2008
Assignee:
Emory University
Inventors:
Stephen F. Traynelis, Dennis C. Liotta, James P. Snyder, Yesim Altas, David D. Mott, James J. Doherty, Jr., Raymond J. Dingledine
Abstract: The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
Type:
Grant
Filed:
October 21, 2003
Date of Patent:
May 13, 2008
Assignee:
Emory University
Inventors:
James P. Snyder, Matthew C. Davis, Brian Adams, Mamoru Shoji, Dennis C. Liotta, Eva M. Ferstl, Ustun B. Sunay
Abstract: The present invention relates to methods of identifying genes involved in memory formation. This is accomplished by performing a gene chip identification of those genes expressed during transcription-dependent memory formation but not during transcription-independent memory formation. A statistical analysis of the gene chip identification output yields a set of genes that are involved in transcription-dependent memory formation.
Type:
Grant
Filed:
August 8, 2005
Date of Patent:
April 15, 2008
Assignees:
Cold Spring Harbor Laboratory, Emory University, Hoffmann-La Roche Inc.
Inventors:
Timothy P. Tully, Joshua I. Dubnau, Michael Davis, Jan Mous, Ulrich Certa
Abstract: Macrolide resistance associated with macrolide efflux (mef) in Streptococcus pneumoniae has been defined with respect to the genetic structure and dissemination of a novel mefE-containing chromosomal insertion element. The mefE gene is found on the 5?-end of a 5.5 kb or 5.4 kb insertion designated mega (macrolide efflux genetic assembly) found in at least four distinct sites of the pneumococcal genome. The element is transformable and confers macrolide resistance to susceptible S. pneumoniae. The first two open reading frames (ORFs) of the element form an operon composed of mefE and a predicted ATP-binding cassette homologous to msrA. Convergent to this efflux operon are three ORFs with homology to stress response genes of Tn5252. Mega is related to mefA-containing element Tn1207.1. Macrolide resistance due to mega has been rapidly increased by clonal expansion of bacteria containing it and horizontally by transformation of previously sensitive bacteria.
Abstract: Methods are provided for enhancing the death of a neaplastic cell comprising the administration of a therapeutically effective concentration of a 14-3-3 antagonist and at least one antineoplastic therapeutic agent. The methods of the invention find use in improving the clinical outcome of a mammal having a neoplastic disorder and comprises administration to a mammal in need thereof at least one antineoplastic therapeutic agent in combination with a 14-3-3 antagonist. Further provided are pharmaceutical compositions having a therapeutically effective amount of a 14-3-3 antagonist and an antineoplastic therapeutic agent. Also provided are methods for identifying agents that selectively inhibit an interaction between a 14-3-3 polypeptide and a 14-3-3 ligand.
Abstract: Constrained paclitaxel derivatives include a bridge extending from the C-3? phenyl to either the C4 or -3 positions. Many of the constrained paclitaxel derivatives provide activity comparable or superior to the natural product paclitaxel.
Type:
Grant
Filed:
January 14, 2005
Date of Patent:
December 25, 2007
Assignees:
Virginia Tech Intellectual Properties, Inc., Binghamton University, Emory University
Inventors:
David George Ian Kingston, Thota Ganesh, James Patrick Synder, Ami S. Lakdawala, Susan Lynn Bane
Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
Type:
Grant
Filed:
March 8, 2004
Date of Patent:
December 11, 2007
Assignees:
Emory University, The University of Georgia Research Foundation, Inc.
Inventors:
Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
Abstract: Methods and devices are provided for administering a drug to a patient's eye. The methods include (a) inserting a hollow microneedle into the sclera or corneal stroma without penetrating across the sclera or corneal stroma; and (b) infusing a fluid drug formulation through the microneedle and into the sclera or cornea. It further may include partially retracting the microneedle before infusion to enhance delivery. Alternatively, the methods may include (a) inserting a solid microneedle into the sclera or corneal stroma without penetrating across the sclera or corneal stroma, wherein the solid microneedle comprises a first quantity of a drug formulation and inserting causes the solid microneedle to form a pocket in the sclera or corneal stroma; and (b) releasing the drug formulation into the pocket to form a drug depot, whereby a drug is released from the depot. The methods and devices may include an array of multiple microneedles.
Type:
Application
Filed:
May 2, 2007
Publication date:
November 8, 2007
Applicants:
Georgia Tech Research Corporation, Emory University
Inventors:
Mark Prausnitz, Ninghao Jiang, Henry Edelhauser
Abstract: The present invention relates to compositions comprising a novel recombinant virus which replicates selectively in cells or tissues that are hypoxic or have an activated HIF pathway. The novel compositions of the invention comprise a recombinant virus genetically engineered to have a hypoxia/HIF-responsive element, or a multiplicity of such elements, operably linked to a promoter which is in turn operably linked to a nucleic acid(s) encoding a peptide(s) which regulates or modulates replication of the virus and/or encode a therapeutic molecule. The invention also includes constructs useful for screening of agents which interact with proteins or genes in the hypoxia-inducible pathway or are jointly translated under hypoxia and animal models useful for monitoring a variety of hypoxic conditions in a non-invasive manner.
Type:
Grant
Filed:
July 26, 2004
Date of Patent:
October 23, 2007
Assignee:
Emory University
Inventors:
Erwin G. Van Meir, Ainsley C. Nicholson, Dawn E. Post